Premium
Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab
Author(s) -
Willenbacher Wolfgang,
Basara Nadesta,
Blau Igor W.,
Fauser Axel A.,
Kiehl Michael G.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02582.x
Subject(s) - daclizumab , medicine , graft versus host disease , refractory (planetary science) , incidence (geometry) , gastroenterology , immunology , disease , surgery , transplantation , tacrolimus , biology , physics , astrobiology , optics
Competitive inhibition of interleukin 2‐dependent lymphocytes by daclizumab demonstrates some beneficial effects in the treatment of graft‐versus‐host disease (GVHD). Sixteen patients with steroid refractory GVHD received daclizumab (1 mg/kg BW) on d 1, 2 (−5), 7, 14 and 21. Twelve patients suffered from grade III–IV acute GVHD and four patients from extensive chronic GVHD. Responses were observed in nine patients (six acute, three chronic GVHD). Fourteen out of 16 patients acquired infections during daclizumab treatment and three deaths were infection related. Daclizumab demonstrates limited activity and is associated with an increased incidence of infectious complications.